Damora Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$210.9 | -$22.3 | -$39.9 | -$61.2 | -$52.2 |
| Net income | -$209.8 | -$21.4 | -$38.3 | -$61.6 | -$51.8 |
| Cash Flow Statement | |||||
| Free cash flow | — | — | — | -$43.1 | -$52.5 |
Shares outstanding 61.7M · Free float 78.5%
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.